Supreme Court Won’t Hear Anti-Vaccine Group’s Free Speech Case
By I. Edwards HealthDay Reporter

TUESDAY, July 1, 2025 — On Monday, the U.S. Supreme Court said it will not hear a case brought by a group once led by U.S. Health Secretary Robert F. Kennedy Jr. that claimed Facebook censored its vaccine-related content.
The Children’s Health Defense sued Meta Platforms, the parent company of Facebook and Instagram. It claimed the company removed their content in violation of free speech rights, NBC News reported.
Kennedy, who is now the U.S. Secretary of Health and Human Services in the Trump administration, founded the group and served as its chairman. It has a history of anti-vaccine activism.
The group argued that Meta colluded with the federal government to silence its posts starting in 2019. Its Facebook page was taken down in 2022 during the COVID-19 pandemic.
The group claimed this violated the First and Fifth Amendments in the U.S. Constitution, NBC News said.
However, lower courts ruled against them. The 9th U.S. Circuit Court of Appeals said there was no solid proof that Meta acted in concert with the government.
Because Meta is a private company, the courts ruled it has the right to decide what content it allows.
The Supreme Court declined to review the case, which means the lower court rulings will still stand. The justices did not comment on their decision, according to NBC News.
Sources
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2025-07-02 06:00
Read more

- Amgen Announces Positive Topline Phase 3 Results for Bemarituzumab in Fibroblast Growth Factor Receptor 2b (FGFR2b) Positive First-line Gastric Cancer
- Results From Amgen's Phase 2 Obesity Study of Monthly MariTide Presented at the American Diabetes Association 85th Scientific Sessions
- After Dobbs, 42 Percent of Surveyed Abortion Providers in Abortion-Ban States Relocated
- 2,770 Cases of Arboviral Disease Reported in 48 States and D.C. in 2023
- 1970 to 2022 Saw Decrease in Overall Heart Disease Mortality
- Digital Inhaler May Predict Acute COPD Exacerbations
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions